Cantor Fitzgerald Research Analysts Decrease Earnings Estimates for Valeant Pharmaceuticals International, Inc. (VRX)

Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX) – Equities research analysts at Cantor Fitzgerald lowered their FY2018 earnings per share (EPS) estimates for shares of Valeant Pharmaceuticals International in a research note issued to investors on Monday. Cantor Fitzgerald analyst L. Chen now anticipates that the specialty pharmaceutical company will post earnings of $3.77 per share for the year, down from their prior estimate of $4.44.

Other equities research analysts also recently issued research reports about the company. Royal Bank of Canada cut their price objective on Valeant Pharmaceuticals International to C$22.50 and set a “sector perform” rating on the stock in a report on Friday, October 20th. TD Securities raised Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a C$25.50 price objective on the stock in a report on Wednesday, November 8th.

Shares of Valeant Pharmaceuticals International (TSE VRX) traded down C$0.42 during mid-day trading on Thursday, hitting C$26.20. The company’s stock had a trading volume of 1,234,800 shares, compared to its average volume of 1,579,086. The firm has a market cap of $9,120.00, a P/E ratio of 5.34 and a beta of -0.67. Valeant Pharmaceuticals International has a 52-week low of C$11.20 and a 52-week high of C$29.28.

In related news, Director Schutter Richard Urbain De bought 10,000 shares of the business’s stock in a transaction on Friday, November 17th. The shares were purchased at an average cost of C$14.33 per share, with a total value of C$143,300.00.

TRADEMARK VIOLATION NOTICE: “Cantor Fitzgerald Research Analysts Decrease Earnings Estimates for Valeant Pharmaceuticals International, Inc. (VRX)” was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/12/30/cantor-fitzgerald-research-analysts-decrease-earnings-estimates-for-valeant-pharmaceuticals-international-inc-vrx.html.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply